Acarbose, an α-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats

K. Nakamura, Shoichi Yamagishi, T. Matsui, T. Yoshida, T. Imaizumi, T. Makino, T. Shimizu, Hiroyoshi Inoue

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Insulin resistance is one of the determinants of post-prandial hyperglycaemia. Recently, acarbose, an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, has been found to reduce the incidence of cardiovascular disease in patients with impaired glucose tolerance or diabetes. However, the molecular mechanism by which acarbose inhibits cardiovascular events remains unknown. In this study, we examined whether oral administration of acarbose could suppress expression of monocyte chemoattractant protein-1 (MCP-1) in fructose-fed rats, a widely used animal model of insulin resistance. Serum MCP-1 levels were elevated in fructose-fed rats after 4 weeks. Acarbose treatment for 4 weeks reduced the fructose-induced elevation of serum MCP-1 levels. Acarbose treatment for 8 weeks decreased MCP-1 mRNA levels in the aortae of fructose-fed rats. These results suggest that the cardioprotective effects of acarbose could be due, at least in part, to the suppression of MCP-1 expression.

Original languageEnglish
Pages (from-to)525-530
Number of pages6
JournalJournal of International Medical Research
Volume34
Issue number5
Publication statusPublished - 2006 Sep
Externally publishedYes

Fingerprint

Acarbose
Glucosidases
Chemokine CCL2
Fructose
Gene expression
Rats
Gene Expression
Serum
Insulin Resistance
Blood Proteins
Insulin
Glucose Intolerance
Medical problems
Hyperglycemia
Small Intestine
Oral Administration
Meals
Aorta
Animals
Cardiovascular Diseases

Keywords

  • Acarbose
  • Antidiabetic agent
  • Atherosclerosis
  • Cardiovascular disease
  • Diabetes
  • Insulin resistance
  • Monocyte chemoattractant protein-1 (MCP-1)
  • Post-prandial hyperglycaemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Acarbose, an α-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats. / Nakamura, K.; Yamagishi, Shoichi; Matsui, T.; Yoshida, T.; Imaizumi, T.; Makino, T.; Shimizu, T.; Inoue, Hiroyoshi.

In: Journal of International Medical Research, Vol. 34, No. 5, 09.2006, p. 525-530.

Research output: Contribution to journalArticle

Nakamura, K. ; Yamagishi, Shoichi ; Matsui, T. ; Yoshida, T. ; Imaizumi, T. ; Makino, T. ; Shimizu, T. ; Inoue, Hiroyoshi. / Acarbose, an α-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats. In: Journal of International Medical Research. 2006 ; Vol. 34, No. 5. pp. 525-530.
@article{4a32b0e09ccc4d9493feebd08d33e927,
title = "Acarbose, an α-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats",
abstract = "Insulin resistance is one of the determinants of post-prandial hyperglycaemia. Recently, acarbose, an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, has been found to reduce the incidence of cardiovascular disease in patients with impaired glucose tolerance or diabetes. However, the molecular mechanism by which acarbose inhibits cardiovascular events remains unknown. In this study, we examined whether oral administration of acarbose could suppress expression of monocyte chemoattractant protein-1 (MCP-1) in fructose-fed rats, a widely used animal model of insulin resistance. Serum MCP-1 levels were elevated in fructose-fed rats after 4 weeks. Acarbose treatment for 4 weeks reduced the fructose-induced elevation of serum MCP-1 levels. Acarbose treatment for 8 weeks decreased MCP-1 mRNA levels in the aortae of fructose-fed rats. These results suggest that the cardioprotective effects of acarbose could be due, at least in part, to the suppression of MCP-1 expression.",
keywords = "Acarbose, Antidiabetic agent, Atherosclerosis, Cardiovascular disease, Diabetes, Insulin resistance, Monocyte chemoattractant protein-1 (MCP-1), Post-prandial hyperglycaemia",
author = "K. Nakamura and Shoichi Yamagishi and T. Matsui and T. Yoshida and T. Imaizumi and T. Makino and T. Shimizu and Hiroyoshi Inoue",
year = "2006",
month = "9",
language = "English",
volume = "34",
pages = "525--530",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "5",

}

TY - JOUR

T1 - Acarbose, an α-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats

AU - Nakamura, K.

AU - Yamagishi, Shoichi

AU - Matsui, T.

AU - Yoshida, T.

AU - Imaizumi, T.

AU - Makino, T.

AU - Shimizu, T.

AU - Inoue, Hiroyoshi

PY - 2006/9

Y1 - 2006/9

N2 - Insulin resistance is one of the determinants of post-prandial hyperglycaemia. Recently, acarbose, an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, has been found to reduce the incidence of cardiovascular disease in patients with impaired glucose tolerance or diabetes. However, the molecular mechanism by which acarbose inhibits cardiovascular events remains unknown. In this study, we examined whether oral administration of acarbose could suppress expression of monocyte chemoattractant protein-1 (MCP-1) in fructose-fed rats, a widely used animal model of insulin resistance. Serum MCP-1 levels were elevated in fructose-fed rats after 4 weeks. Acarbose treatment for 4 weeks reduced the fructose-induced elevation of serum MCP-1 levels. Acarbose treatment for 8 weeks decreased MCP-1 mRNA levels in the aortae of fructose-fed rats. These results suggest that the cardioprotective effects of acarbose could be due, at least in part, to the suppression of MCP-1 expression.

AB - Insulin resistance is one of the determinants of post-prandial hyperglycaemia. Recently, acarbose, an α-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, has been found to reduce the incidence of cardiovascular disease in patients with impaired glucose tolerance or diabetes. However, the molecular mechanism by which acarbose inhibits cardiovascular events remains unknown. In this study, we examined whether oral administration of acarbose could suppress expression of monocyte chemoattractant protein-1 (MCP-1) in fructose-fed rats, a widely used animal model of insulin resistance. Serum MCP-1 levels were elevated in fructose-fed rats after 4 weeks. Acarbose treatment for 4 weeks reduced the fructose-induced elevation of serum MCP-1 levels. Acarbose treatment for 8 weeks decreased MCP-1 mRNA levels in the aortae of fructose-fed rats. These results suggest that the cardioprotective effects of acarbose could be due, at least in part, to the suppression of MCP-1 expression.

KW - Acarbose

KW - Antidiabetic agent

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Diabetes

KW - Insulin resistance

KW - Monocyte chemoattractant protein-1 (MCP-1)

KW - Post-prandial hyperglycaemia

UR - http://www.scopus.com/inward/record.url?scp=33751053996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751053996&partnerID=8YFLogxK

M3 - Article

C2 - 17133782

AN - SCOPUS:33751053996

VL - 34

SP - 525

EP - 530

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 5

ER -